In this article, we will discuss Tivozanib (Mechanism of Action). So, let’s get started.
Mechanism of Action
Tivozanib is a tyrosine kinase inhibitor. In vitro cellular kinase assays demonstrated that tivozanib inhibits phosphorylation of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2 and VEGFR-3 and inhibits other kinases including c-kit and PDGFR β at clinically relevant concentrations. In tumor xenograft models in mice and rats, tivozanib inhibited angiogenesis, vascular permeability, and tumor growth of various tumor cell types including human renal cell carcinoma.
Tivozanib exposure-response relationships and the time course of pharmacodynamic response have not been fully characterized.
At the recommended dose of Tivozanib, no large mean increases (i.e., 20 msec) in QTc interval were observed.